

| | | | |
|--|--|---|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 20750-050US1 | Application No. 10/593,847 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant John Robert Fritch, et al. | |
| | | Filing Date August 2, 2007 | Group Art Unit |

| U.S. Patent Documents | | | | | | | |
|-----------------------|-----------|-----------------|------------------|-----------------------|-------|----------|----------------------------|
| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
| | A1 | US 4099012 | 7/04/78 | Gshwend | | | |
| | A2 | US 4405644 | 9/20/83 | Kabbe et al. | | | |
| | A3 | US 4409231 | 10/11/83 | Stenzel et al. | | | |
| | A4 | US 4985352 | 1/15/91 | Julius et al. | | | |
| | A5 | US 5077409 | 12/31/91 | Wissner | | | |
| | A6 | US 5128351 | 7/07/92 | Wissner | | | |
| | A7 | US 5523280 | 6/04/96 | Chene et al. | | | |
| | A8 | US 5661024 | 8/26/97 | Kao et al. | | | |
| | A9 | US 5886044 | 3/23/99 | Widdowson et al. | | | |
| | A10 | US 5905080 | 5/18/99 | Duckworth et al. | | | |
| | A11 | US 5945382 | 8/31/99 | Cantegril et al. | | | |
| | A12 | US 5990133 | 11/23/99 | Gaster et al. | | | |
| | A13 | US 6005008 | 12/21/99 | Widdowson et al. | | | |
| | A14 | US 6028085 | 2/22/00 | Bromidge | | | |
| | A15 | US 6054472 | 4/25/00 | Armistead et al. | | | |
| | A16 | US 6107324 | 08/ /02 | Behan et al. | | | |
| | A17 | US 6140509 | 10/31/00 | Behan et al. | | | |
| | A18 | US 6271261 | 8/07/01 | Widdowson | | | |
| | A19 | US 2002/0025965 | 2/28/02 | Lavielle et al. | | | |
| | A20 | US 6417393 | 7/09/02 | Christophersen et al. | | | |
| | A21 | US 6479480 | 11/12/02 | Moyes et al. | | | |
| | A22 | US 6479519 | 11/12/02 | Astles et al. | | | |
| | A23 | US 6541209 | 4/01/03 | Behan et al. | | | |
| | A24 | US 6706749 | 3/16/04 | Dahl et al. | | | |
| | A25 | US 2004/0102636 | 5/27/04 | Miller et al. | | | |
| | A26 | US 6784183 | 8/31/04 | Lavielle et al. | | | |
| | A27 | US 2005/0080124 | 04/14/2005 | Teegarden et al. | | | |

| | |
|--|-----------------------------------|
| Examiner Signature /Samantha Shterengarts/ | Date Considered 08/14/2009 |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | |
|--|--|---|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 20750-050US1 | Application No. 10/593,847 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant John Robert Fritch, et al. | |
| | | Filing Date August 2, 2007 | Group Art Unit |

| Foreign Patent Documents or Published Foreign Patent Applications | | | | | | | |
|--|-----------|-----------------|------------------|--------------------------|-------|----------|-------------|
| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation |
| | | | | | | | Yes No |
| | A28 | WO 96/02138 | 2/01/96 | WIPO | | | |
| | A29 | WO 96/10559 | 4/11/96 | WIPO | | | |
| | A30 | WO 97/03967 | 2/06/97 | WIPO | | | |
| | A31 | WO 97/45111 | 12/04/97 | WIPO | | | |
| | A32 | WO 98/24785 | 6/11/98 | WIPO | | | |
| | A33 | WO 99/06354 | 2/11/99 | WIPO | | | |
| | A34 | WO 99/32436 | 7/01/99 | WIPO | | | |
| | A35 | WO 99/32463 | 7/01/99 | WIPO | | | |
| | A36 | WO 99/52927 | 10/21/99 | WIPO | | | |
| | A37 | WO 00/57877 A1 | 10/05/00 | WIPO | | | |
| | A38 | WO 2000/064866 | 11/02/00 | WIPO | | | |
| | A39 | WO 2001/021160 | 3/29/01 | WIPO | | | |
| | A40 | WO 01/29008 | 4/26/01 | WIPO | | | |
| | A41 | EP 1108720 A1 | 6/20/01 | Europe | | | |
| | A42 | WO 2002/039987 | 5/23/02 | WIPO | | | |
| | A43 | WO 02/076464 | 10/03/02 | WIPO | | | |
| | A44 | WO 03/062206 | 7/31/03 | WIPO | | | |
| | A45 | WO 04/028450 | 4/08/04 | WIPO | | | |
| | A46 | WO 04/058722 | 7/15/04 | WIPO | | | |
| | A47 | WO 2004/071426 | 8/26/04 | WIPO | | | |
| | A48 | WO 2004/085433 | 10/07/04 | WIPO | | | |
| | A49 | WO 04/096771 | 11/11/04 | WIPO | | | |
| | A50 | WO 2006/018662 | 2/23/06 | WIPO | | | |
| | A51 | WO 2006/049941 | 5/11/06 | WIPO | | | |
| | A52 | WO 2006/060654 | 6/08/06 | WIPO | | | |
| | A53 | WO 2006/076592 | 7/20/06 | WIPO | | | |
| | A54 | WO 2006/089871 | 8/31/06 | WIPO | | | |

| | |
|--|-----------------|
| Examiner Signature | Date Considered |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | |
|--|--|---|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 20750-050US1 | Application No. 10/593,847 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant John Robert Fritch, et al. | |
| | | Filing Date August 2, 2007 | Group Art Unit |

| Foreign Patent Documents or Published Foreign Patent Applications | | | | | | | |
|--|-----------|-----------------|------------------|--------------------------|-------|----------|-------------|
| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation |
| | | | | | | | Yes No |
| | A55 | WO2006/081335 | 8/3/06 | WIPO | | | |
| | A56 | EP 1734039 | 12/20/06 | Europe | | | |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|--|-----------|--|
| Examiner Initial | Desig. ID | Document |
| | A57 | Andrzejewska-Buczko et al., "Serotonin in diabetic retinopathy", <i>Klin Oczna</i> 1996 Feb; 98(2):101-4 (abstract only) |
| | A58 | Berge et al., "Pharmaceutical salts", <i>J. of Pharmaceutical Sciences</i> (1977) 66(1):1-19 |
| | A59 | Cameron et al., "The effects of 5-hydroxytryptamine 5-HT2 receptor antagonists on nerve conduction velocity and endoneurial perfusion in diabetic rats", <i>Naunyn Schmiedebergs Arch Pharmacol</i> , 2003 Jun; 367(6):607-14 |
| | A60 | Casey et al., "Constitutively active mutant 5HT _{2A} serotonin receptors: inverse agonist activity of classical 5HT _{2A} antagonists", <i>Society for Neuroscience Abstracts</i> , Vol. 22, p. 699.10 |
| | A61 | Cazzola et al., "5-HT modifiers as a potential treatment of asthma", <i>TIPS</i> , 2000, Vol. 21, p.13 |
| | A62 | Chang et al., "Mechanism of the ocular hypotensive action of ketanserin", <i>J Ocul Pharmacol.</i> , 1985 Summer; 1(2):137-47 |
| | A63 | Cohen-Mansfield et al., "Agitated behaviors in the elderly. I. A conceptual review", <i>J. Am. Geriatr. Soc.</i> , 1986 Oct; 34(10):711-21 |
| | A64 | Collier et al., "Radiosynthesis and in-vivo evaluation of the pseudopeptide δ-opioid antagonist [¹²⁵ I]-ITIPP(ψ)", <i>J. Labeled Compd. Radiopharm.</i> , 1999, Vol. 42, pp. S264-S266 |
| | A65 | Collins, et al., "N-Phenylamidines as Selective Inhibitors of Human Neuronal Nitric Oxide Synthase: Structure-Activity Studies and Demonstration of in Vivi Activity", <i>Journal of Medicinal Chemistry, American Chemical Society</i> , 41, no. 15, pp. 2858-2871, 1998; XP0022144154. |
| | A66 | De Bie et al., "Modulation of airway hyperresponsiveness and eosinophilia by selective histamine and 5-HT receptor antagonists in a mouse model of allergic asthma", <i>British Journal of Pharmacology</i> , 1998, Vol. 124:857-864 |
| | A67 | Greene et al., <i>Protecting Groups in Organic Synthesis</i> , 3 rd Edition, 1999 (Wiley)* |
| | A68 | Grunder et al., "Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography", <i>Neuropsychopharmacology</i> , 1997 Sep; 17(3):175-85 |
| | A69 | Herrick-Davis et al., "Activating mutations of the serotonin 5-HT2C receptor", <i>J. Neurochem.</i> , 1997 Sep; 69(3):1138-44 |
| | A70 | Herrick-Davis et al., "Constitutively active 5HT2C serotonin receptor created by site-directed mutagenesis", <i>Society for Neuroscience Abstracts</i> , Vol. 22, p. 699.18 |
| | A71 | Higuchi et al., "Pro-drugs and Novel Delivery Systems", Vol. 14 of the ACS Symposium Series; and in <i>Bioreversible Carriers in Drug Design</i> , ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987* |

| | |
|--|-----------------|
| Examiner Signature | Date Considered |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | |
|--|--|---|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 20750-050US1 | Application No. 10/593,847 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant John Robert Fritch, et al. | |
| | | Filing Date August 2, 2007 | Group Art Unit |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|--|-----------|--|
| Examiner Initial | Desig. ID | Document |
| | A72 | Katz et al., "Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group", J. Clin. Psychiatry, 1999 Feb; 60(2):107-15 |
| | A73 | Koss et al., "Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory. The Alzheimer's Disease Cooperative Study", Alzheimer Dis Assoc Disord. 1997; 11 Suppl 2:S45-50. |
| | A74 | Landolt et al., "Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra", Neuropsychopharmacology, 1999 Sep; 21(3):455-66 |
| | A75 | Le Bas et al., "Radioiodinated analogs of EP 00652218 for the exploration of the tachykinin NK1 receptor by spect", J. Labeled Compd. Radiopharm., 2001, Vol 44:S280-S282 |
| | A76 | Mastropasqua et al., "Ocular hypotensive effect of ketanserin in patients with primary open angle glaucoma", Acta Ophthalmol Scand Suppl., 1997 (224):24-5 |
| | A77 | National Institutes of Health, National Heart, Lung and Blood Institute, "Insomnia" (October 1995) pp. 1-4. |
| | A78 | Pietraszek et al., "Blood serotonergic mechanisms in type 2 (non-insulin-dependent) diabetes mellitus", Thromb Res., 1992 Jun 15; 66(6):765-74 |
| | A79 | Prosser et al., "Selective serotonin 5-HT _{2A} inverse agonists promote sleep consolidation in male Wistar rats during the normal inactive phase", #29, Arena Pharmaceuticals, Inc., APSS Meeting (June 2004) 1 page. |
| | A80 | Remington, The Science and Practice of Pharmacy, 20 th Edition, 2000 (Lippincott Williams & Wilkins)* |
| | A81 | Satomura et al., "Sarpogrelate, a specific 5HT2-receptor antagonist, improves the coronary microcirculation in coronary artery disease", Clin. Cardiol. 2002 Jan; 25(1):28-32 |
| | A82 | Sharpley et al., "Slow wave sleep in humans: role of 5-HT2A and 5-HT2C receptors", Neuropharmacology, 1994 Mar-Apr; 33(3-4):467-71 |
| | A83 | Smith et al., "Test-retest variability of serotonin 5-HT2A receptor binding measured with positron emission tomography and [18F]altanserin in the human brain, Synapse, 1998 Dec; 30(4):380-92 |
| | A84 | Staley et al., "Comparison of [(18)F] altanserin and [(18)F]durtroaltanserin for PET imaging of serotonin (2A) receptors in baboon brain: pharmacological studies, Nucl Med Biol, 2001 Apr; 28(3):271-9 |
| | A85 | Strah-Pleynet et al., "Discovery and SAR of novel 5-HT _{2A} inverse-agonists", 227 ACS National Meeting, MEDI 270, Arena Pharmaceuticals, Inc. (March 2004), 1 page. |
| | A86 | Street et al., "Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group", Arch Gen Psychiatry, 2000 Oct; 57(10):968-76 |
| | A87 | Takahashi et al., "Sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy", Diabetes Res Clin Pract. 2002 Nov, 58(2):123-9 |
| | A88 | Takenaka et al., "The effect of anplag (sarpogrelate HCl), novel selective 5-HT ₂ antagonist on intraocular pressure in glaucoma patients", Investig Ophthalmol Vis Sci, 36(4):S724 (3390-377) |
| | A89 | Talvik-Lotfi et al., "High 5HT2A receptor occupancy in M100907-treated schizophrenic patients", Psychopharmacology (2000) 148:400-403 |

| | |
|--|-----------------|
| Examiner Signature | Date Considered |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | |
|--|--|---|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 20750-050US1 | Application No. 10/593,847 |
| Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b)) | | Applicant John Robert Fritch, et al. | |
| | | Filing Date August 2, 2007 | Group Art Unit |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|--|-----------|--|
| Examiner Initial | Desig. ID | Document |
| | A90 | The International Classification of Sleep Disorders, Revised Diagnostic and Coding Manual, American Academy of Sleep Medicine (2001) pp. 1-336 (also includes table of contents and glossary) |
| | A91 | Topliss, John G., "A Manual Method for Applying the Hansch Approach to Drug Design", <i>Journal of Medicinal Chemistry</i> , Vol. 20, No. 4, pp. 463-469, 1997. |
| | A92 | Wilson et al., "LY53857, a 5HT2 Receptor Antagonist, Delays Occlusion and Inhibits Platelet Aggregation in a Rabbit Model of Carotid Artery Occlusion", <i>Thromb Haemost</i> . 1991 Sep 2; 66(3):355-60 |
| | A93 | Winokur et al., "Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study", <i>Biol Psychiatry</i> , 2000 Jul 1; 48(1):75-8 |
| | A94 | Zhu et al., "Synthesis and mode of action of [¹²⁵ I]- and ³ H-labeled Thieno -2,3-c]pyridine antagonists of cell adhesion molecule expression", <i>J. Org. Chem.</i> , (200) 67:943-8 |
| | A95 | Copy of International Search Report dated November 8, 2004, for International Application No. PCT/US2004/023880. |

* Not enclosed, available upon request

| | |
|--|-------------------------------|
| Examiner Signature <i>/Samantha Shterengarts/</i> | Date Considered 08/14/2009 |
| EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |